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Abstract
This study investigates measurement biases in longitudinal positron-emission tomography/computed tomography
(PET/CT) studies that are due to instrumentation variability including human error. Improved estimation of variability
between patient scans is of particular importance for assessing response to therapy and multicenter trials. We used
National Institute of Standards and Technology–traceable calibration methodology for solid germanium-68/gallium-68
(68Ge/68Ga) sources used as surrogates for fluorine-18 (18F) in radionuclide activity calibrators. One cross-calibration
kit was constructed for both dose calibrators and PET scanners using the same 9-month half-life batch of 68Ge/68Ga in
epoxy. Repeat measurements occurred in a local network of PET imaging sites to assess standardized uptake value
(SUV) errors over time for six dose calibrators from two major manufacturers and for six PET/CT scanners from three
major manufacturers. Bias in activity measures by dose calibrators ranged from−50% to 9% andwas relatively stable
over time except at one site that modified settings between measurements. Bias in activity concentration measures
by PET scanners ranged from −27% to 13% with a median of 174 days between the six repeat scans (range, 29 to
226 days). Corresponding errors in SUV measurements ranged from−20% to 47%. SUV biases were not stable over
time with longitudinal differences for individual scanners ranging from −11% to 59%. Bias in SUV measurements
varied over time and between scanner sites. These results suggest that attention should be paid to PET scanner
calibration for longitudinal studies and use of dose calibrator and scanner cross-calibration kits could be helpful for
quality assurance and control.
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Introduction
Molecular imaging with combined positron-emission tomography
(PET) and X-ray computed tomography (CT) scanners has become
a standard component of diagnosis and staging in oncology [1,2].
In addition to cancer detection and staging, PET/CT imaging is be-
coming more important as a quantitative biomarker for monitoring
response to therapy and an evaluation tool for new drug therapies
[3–5]. The most common radiotracer is fluorine-18 (18F)-radiolabeled
fluorodeoxyglucose (FDG) [6].
PET/CT scanners are designed to measure in vivo radioactivity
concentration (kBq/ml) with users particularly interested in the
relative tissue uptake of radiotracer in targeted areas versus uptake
in normal tissue in the same patient. The two most significant
sources of variation that occur in practice are amount of injected
tracer and patient size. As a first-order compensation for these varia-
tions, the standardized uptake value (SUV) is commonly used as a
relative measure of tracer uptake [7]. The basic expression for a
SUV (g/ml) is:
SUV =
A
ðI=WÞ ð1Þ
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where A is the decay-corrected radioactivity activity concentration
(kBq/ml) measured by the PET scanner within a region of interest
(ROI), I is the decay-corrected amount of injected radiotracer (MBq),
and W is the patient weight (kg), which is used as a surrogate for a
distribution volume of tracer, with some sites preferring lean body
mass or body surface area instead of weight. If all the injected radio-
tracer is retained and uniformly distributed throughout the body, the
SUV everywhere will be 1 g/ml regardless of the amount of radiotracer
injected or patient size. Ideally, the use of SUVs removes variability
introduced by differences in patient size and the amount of injected
radiotracer to facilitate comparison of the relative tracer uptake between
tissues in the same patient or between lesions in different patients. An
SUV from whole-body imaging is analogous to a brain tissue uptake
ratio with a critical difference of a tissue uptake ratio using a second
PET scanner measure of activity concentration in normal background
tissue in place of the ratio of injected dose to weight used in SUV. The
same instrument makes the two ROI activity measures in brain tissue
uptake measures, so it could be reasonable to assume that any instru-
ment calibration errors will cancel each other out. Three instruments
consisting of a PET scanner, dose calibrator, and weight scale collect
measurements for the weight-based SUV calculation, so any changing
individual measurement biases in the different instruments due to
measurement error or longitudinal drifts between calibrations could
result in different SUV measurement biases for each PET scanner. In
practice, there are several sources of bias and variance that are intro-
duced in the measurement process. For example, in estimating SUVs
for FDG uptake in tumors, there are biological factors as well as instru-
mentation factors that affect the SUV measurement [8–10].
The dose calibrator, which is required for quantitative PET imaging, is
one of the potential sources of error in global scaling of PET image values
and SUV calculations. ANational Institute of Standards and Technology
(NIST)–traceable mock dose standard for 18F was developed to create
a means of monitoring accuracy and precision in dose calibrator mea-
surements of 18F-labeled PET tracers [11]. As much as a 10% shift in
calibration was observed when comparing dose calibrator models from
different manufacturers of dose calibrators [12]. Thus, it is important
to understand the longitudinal variability of an individual dose calibrator
used for both scanner calibration and patient SUV measurements and
any potential differences in longitudinal drift of measurement biases
between the dose calibrator and PET scanner.
In principle, regular calibration of PET scanners should generate
a global scanner calibration factor to correct for global sensitivity
variations and any longitudinal drifts in individual sensor measure-
ments. However, scanner calibrations typically occur monthly, quar-
terly, semiannually, and annually, (or not at all) and so cannot
compensate for longitudinal drifts in PET measurement variations in
the global scanner calibration factor that occur on a time scale shorter
than months. There is little information available on the time-varying
behavior of the global scanner calibration factor. Studies by Doot et al.
show that for a period of minutes to a few hours, the global efficiency
variation is approximately 0.3% for the General Electric (GE) Dis-
covery STE (DSTE) PET scanner used in this study [13]. For longer
periods (months to years), a recent study by Lockhart et al. indicated
that, with careful calibration procedures, there is approximately 4%
variability introduced by scanner calibration [14]. In this study, we
use the NIST-traceable 18F dose calibrator standard to construct an
implicitly traceable 18F PET scanner standard to analyze the long-term
variations in PET scanner and dose calibrator instrumentation factors
that affect the accuracy of SUVs. This manuscript expands an abstract
presented at the 57th Annual Society of Nuclear Medicine (SNM)meet-
ing [15] and summary results based on preliminary local site analyses
[16] using more robust central analysis of Digital Imaging and Com-
munications in Medicine (DICOM) files from all sites.
Materials and Methods
Phantom Design
The cross-calibration system consisted of two components as shown
in Figure 1 [17]. The first is a NIST-traceable dose calibrator 18F
mock dose standard [11] constructed from germanium-68/gallium-68
(68Ge/68Ga) in epoxy (RadQual, LLC, Weare, NH). From the same
batch of 68Ge/68Ga in epoxy, an implicitly traceable 18F surrogate source
for PET scanners was constructed (Figure 1). The PET scanner sur-
rogate source was a 6 × 6-cm cylinder. The size was chosen on the
basis of opposing constraints; avoiding resolution loss (also called partial
volume errors) in a central ROI, versus avoiding unrealistic count-rate
effects due to excessive total activity in the scanner field of view. The
cylindrical 68Ge/68Ga source was attached to the bottom of a modi-
fied American College of Radiology (ACR) PET phantom in place
of the standard cold rod component as shown in Figure 1. A PET
cross-calibration kit (PET F-18 X-Cal System, RadQual, LLC) is
commercially available. It is similar to the prototype described in this
manuscript except the surrogate cylinder size was reduced to 4.5 ×
4.5 cm and a third 68Ge/68Ga source was added for cross-calibration
of well counters [16].
Scanning Protocol
Weight-normalized SUVs were used, with the patient weight of the
phantom entered as 70 kg into PET scanners for all imaging sessions
because variation in PET values due to body habitus measures was not
of interest in this study. The same PET cross-calibration kit was sent
to all participating sites twice to allow longitudinal measurements.
Some of the community PET imaging centers required that we did
not change any of their dose calibrator or PET scanner parameters from
their normal 18F settings used for their whole-body oncology 18F-FDG
PET scans. Therefore, we measured 18F activities, activity concentra-
tions, and weight-normalized SUV of the kit’s two 68Ge/68Ga sources
at all six sites using each site’s whole-body clinical PET settings for
18F-FDG scans and corrected to equivalent 68Ge/68Ga values. The
68Ge/68Ga scanner source was rescanned using 68Ge/68Ga settings
during 8 of the 12 imaging sessions to allow comparison between 68Ge/
68Ga concentrations calculated from 18F and 68Ge/68Ga PET images.
Figure 1. PET cross-calibration kit. One batch of epoxy contain-
ing 68Ge/68Ga was used to construct solid 68Ge/68Ga mock dose
calibrator and surrogate scanner sources with identical activity
concentrations [17].
Translational Oncology Vol. 7, No. 1, 2014 Biases in Longitudinal PET Measurements Doot et al. 49
PET Imaging Centers’ Characteristics and Equipment
Activity in the same 68Ge/68Ga dose calibrator mock dose source
and activity concentration in the corresponding 68Ge/68Ga PET
scanner surrogate source were measured twice at six sites using
the equipment listed in Table 1. The PET scanner measurements
were made between May 2009 and April 2010. The repeat measure-
ment occurred after a regularly scheduled PET scanner calibration
(range of 29 to 226 days between measurements). Measurements
were assessed using PET/CT scanners from three major manufac-
turers (GE Healthcare Technologies, Milwaukee, WI; Philips Health-
care, Eindhoven, The Netherlands; and Siemens Medical Solutions
USA, Knoxville, TN) and dose calibrators from two major manu-
facturers (Biodex Medical Systems, Shirley, NY and Capintec, Inc,
Ramsey, NJ).
Common “True” 68Ge/ 68Ga Activity Concentration Reference
A common “true” reference 68Ge/68Ga activity concentration, AX,
on the reference date (T R) of 3 October 2008 was calculated by
dividing the 1.469 MBq activity (ax) of the batch of
68Ge/68Ga in
epoxy measured by RadQual by the ratio of the RadQual-reported
epoxy weight of 3 g (WE) to epoxy density of 1.10 g/ml (ρ).
Activity Measurements of 68Ge/ 68Ga Mock Syringe in
Dose Calibrators
The dose calibrator 18F setting was used to measure the activity of
the RadQual mock dose (aD) on the experiment date (T E ) to enable
detection of changes in dose calibrator settings between measure-
ments. The corresponding 68Ge activity (ag) on T E was then calcu-
lated by multiplying aD by the relative response factor (F ) of 1.054
between 68Ge/68Ga and 18F dose calibrator measurements of the
RadQual mock syringe as determined by the NIST [11]. The activity
concentration of the 68Ge/68Ga epoxy in the mock dose (AD) was
calculated by the equation
AD =
aD  F  ρ
WE
ð2Þ
by also accounting for the 68Ge epoxy density and weight. The refer-
ence date (T R) of
68Ge activity concentration (AC) was then calculated
by the equation
AC = AD  eðλG ðTETRÞÞ ð3Þ
where λG is the
68Ge/68Ga decay constant, which equals natural loga-
rithm of 2 divided by RadQual-recommended half-life of 68Ge of
270.8 days [18]. The reference date (T R) dose calibrator measured
68Ge activity (aG ) was calculated by substituting aG and ag for AC
and AD in Equation 3.
Activity Concentrations of 68Ge/ 68Ga Sources from
18F and 68Ga Images
Mean activity concentration measurements in SUV units were
extracted automatically from PET images using a cubical ROI
with a volume of 3.375 cm3 and sides of 1.5 cm centered in the
middle of the 68Ge/68Ga scanner source using a plug-in application
written in Objective-C for OsiriX open-source imaging software
version 5.0 (Pixmeo SARL, Bernex, Switzerland).
For DICOM slices acquired during the first bed position, we con-
vert measured SUV (SM) into Bq/ml units decay corrected to the start
of acquisition, A1S (activity at time T 1S), using the equation
A1S = SM  AI  e
ðλF ðT1STiÞÞ
W  103
 
ð4Þ
where the bracketed factor is from Quantitative Imaging Biomarkers
Alliance SUV pseudocode (http://qibawiki.rsna.org/index.php?title=
Standardized_Uptake_Value_%28SUV%29) and W is patient weight
in the DICOM header field (0010,1030) resulting from a value of
70 kg entered by the PET scanner operator. We entered 70 kg for
patient weight in PET scanners to avoid errors associated with scanner
manufacturers’ various methods of rounding entered weight values.
The decay factor d for 18F radionuclides was computed as
d = eðλF ðTmT1S ÞÞ ð5Þ
where λF is the
18F decay constant, Tm = T 1M for slices in the first
bed position and Tm = T 2M for slices in the second bed position. For
the Philips PET scanners, we define Tm equal to the average of the
two acquisitions’ mid time points of T 1M and T 2M. The resulting
dvalues were similar to DICOM DecayFactor field (0054,1321)
for GE and Siemens PET scanners (average difference was −0.4 ±
0.6%, ± SD; n = 10) but not similar for Philips scanners, which
populated this field with a nominal value of 1. We used decay factor
d calculated by Equation 5 instead of DICOM DecayFactor field
(0054,1321) to uncorrect the amount of 18F decay correction used
Table 1. PET/CT Scanner and Dose Calibrator Descriptions.
Trial Site PET/CT Manufacturer and Model PET Reconstruction Method Dose Calibrator Manufacturer and Model
MMC* Siemens Biograph TruePoint 3D-OSEM, 4i8s† Biodex Atomlab 100
PIC‡ General Electric DST 2D-OSEM, 2i30s† Capintec CRC-15R
SCCA§ General Electric DSTE 2D-FBP¶ Capintec CRC-15R
SVH# Siemens Biograph 6 3D-OSEM, 2i8s† Biodex Atomlab 100
UWMC** General Electric DSTE 2D-FBP¶ Capintec CRC-127R
UWMC** Annex Philips Gemini TF TOF 3D-BLOB-TF†† Capintec CRC-15W
*Multicare Medical Center, Tacoma, WA 98405.
†3-Dimensional space (3D) or 2-D dimensional space (2D) subsets expectation maximization (OSEM), iterations (i), and subsets (s).
‡Providence Imaging Center, Anchorage, AK 99508.
§Seattle Cancer Care Alliance, Seattle, WA 98109.
¶2-Dimensional space (2D), filtered back projection (FBP).
#Skagit Valley Hospital’s Regional Cancer Care Center, Mount Vernon, WA 98273.
**University of Washington Medical Center, Seattle, WA 98195.
††This 3D lines of response–based iterative row-action maximum-likelihood algorithm incorporates time-of-flight information.
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by scanners when imaging 68Ge/68Ga sources in 18F acquisition
mode to enable consistent quantitative correction of PET images
from all three PET scanner manufacturers.
We then compensate for the scanners’ 18F decay correction of the
68Ge/68Ga activity concentration from the acquisition start, A1S, to
the middle of the acquisition, T 1M, corrected for the difference be-
tween the 68Ge/68Ga and 18F branching ratios (positron fractions),
and finally decay corrected to the reference time T R. The corrected
activity concentration is named AF and defined by the equation
AF =
A1S
d
 fF
fG
 eðλG ðTETRÞÞ ð6Þ
where fF and fG are the positron fractions for
18F and 68Ge/68Ga
radionuclide decays. We used the positron fraction values provided
in each manufacturer’s DICOM field (0018,1076) from the 18F and
68Ge/68Ga scans. Activity concentrations of the 68Ge/68Ga source
from 68Ge/68Ga PET images were decay corrected to reference time
T R by the equation
AG = Ag  eðλG ðTETRÞÞ ð7Þ
where Ag is activity concentrations of the
68Ge source from 68Ge/
68Ga images on the experiment date T E .
Error Analysis
Biases in the dose calibrator measurements (ED) were calculated
by subtracting assumed true activity, ax, from aG and dividing the
result by ax. Biases in the PET scanner measurements (EA) were
similarly estimated by subtracting AX from AG and dividing the re-
sult by AX. Biases in SUV measures (ES ) were then calculated by
the equation
ES =
ð1 + EAÞ
ð1 + EDÞ − 1 ð8Þ
where the error in the measurement of body habitus (i.e., weight,
lean body mass, or body surface area) in the SUV calculation is
assumed to be negligible relative to the body habitus value. Biases be-
tween 68Ge/68Ga activities calculated from 18F and 68Ge/68Ga PET
images were determined by subtracting AG from AF and dividing
the result by AG .
Percentage biases in activity measures by dose calibrators were
related to equipment manufacturers using the unpaired rank score
t test.
Results
Figure 1 shows the two 68Ge/68Ga sources in the PET calibration
kit [17] including an image of the cylindrical 68Ge/68Ga surrogate source
inside a modified ACR phantom for PET scanner measurements. Fig-
ure 2 exhibits a sample CT cross section of the modified ACR phantom
Figure 2. PET cross-calibration 68Ge/68Ga source for the scanner assembled in a modified ACR phantom in a CT image with a 10-cm
white scale bar (A) and sample axial PET slices with 18F activity in ACR PET lid cylinders and in the ACR phantom background from one
site using analytical PET reconstruction (B) and another site employing iterative reconstruction (C). Air voids in the 68Ge epoxy are
apparent at the top and bottom of the cylinder in the CT image.
Figure 3. Transaxial linear activity profiles from one PET scan of
same 68Ge/68Ga surrogate source from the first visit to all sites
(n = 6). Transaxial linear activity profiles from three adjacent central
axial slices were averaged and normalized by the average profile
center activity values. A ringing artifact is apparent in profile (open
circles) from the Philips Gemini TF TOF PET scan.
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and sample images from one site using analytical PET image recon-
struction and another site using iterative PET reconstruction.
The patient weight in the DICOM header field (0010,1030) was
69.95 ± 0.06 kg (± SD, n = 12) due to each PET scanner manufac-
turer storing the manually entered 70 kg as a different value (70.000
for GE, 69.916 for Siemens, and 69.850 for Philips PET scanners).
The assumption of negligible error in the body habitus value in Equa-
tion 8 is reasonable because the SD in the patient weight values was
only 0.09% of the operator-entered reference value of 70 kg in our
phantom study.
The average difference between 68Ge/68Ga activity concentrations
estimated from 18F and 68Ge/68Ga PET images was 0.1 ± 1.6%
(range, −1.9%-3.7%; n = 8). The small average difference in calcu-
lated PET bias from 18F and 68Ge/68Ga PET scans indicates that it
is feasible to calculate bias from 18F scans of 68Ge/68Ga sources. Sub-
sequently reported values are based on 68Ge/68Ga activity concentra-
tions extracted from 18F PET images.
The plot of transaxial linear activity profiles from all sites in
Figure 3 indicates that the employed cubical ROI with a volume
of 3.375 cm3 and sides of 1.5 cm will not experience partial volume
measurement errors when centered in the source.
Table 2 shows longitudinal changes in errors in individual PET
dose calibrator and scanner measurements ranged from −59% to
1% for dose calibrators and from −23% to 11% for PET scanners.
Table 3 displays the corresponding longitudinal change in SUV mea-
surement bias ranged from −11% to 59%. The site order in Table 1
was randomly changed for use in column 1 of Tables 2 and 3 to
protect the identity of any site with unexpected large measurement
errors such as site 1 in Tables 2 and 3. The fourth and fifth sites in
Tables 2 and 3 used Atomlab dose calibrators (Biodex Medical Sys-
tems), whereas the other four sites used Capintec dose calibrators.
Individual site results were relayed to each site so corrective actions
could be taken if warranted by local quality control or quality assur-
ance protocols. The dose calibrator error measurements correlated to
equipment manufacturer after censoring the outlying −50% bias data
point at site 1 (P = .001, n = 11).
Discussion
By using a NIST-traceable mock dose source for the dose calibrator
measurement and an implicitly traceable surrogate source for PET
scanner measurements, we were able to estimate the absolute measure-
ment bias for both dose calibrators and PET scanners for 18F sources
(Tables 2 and 3) and 68Ge/68Ga sources. From these measurement
biases, we can then calculate the error in SUV estimation assuming
the sources of bias are the same for patients and the phantom and
no operator or patient weighing errors occurred during a patient scan.
The scan protocol in our studies used a 68Ge/68Ga surrogate source
in the PET scanner using an 18F acquisition protocol. This was moti-
vated by the desire to use the most common clinical scan protocol at
each site, which was primarily an FDG multibed 18F acquisition pro-
tocol. This approach simplified the acquisition process. However, the
use of the 18F half-life (110 minutes), instead of the actual 68Ge half-
life (271 days), meant that post-reconstruction correction to the image
data was a requirement. The corrections were complicated, requiring
removing the effect of the 18F positron fraction and half-life per bed
position and then correction for 68Ge/68Ga positron fraction and half-
life. Although the corrections were straightforward in concept as
shown in Equations 4 through 7, it is likely that similar bias calcula-
tions derived from 18F scans of 68Ge sources will be limited unless
PET scanner manufacturers can be convinced to provide the bias
calculation software. Due to the complexity of corrections required
to determine PET biases from 18F images of 68Ge/68Ga sources, we
recommend PET biases be calculated from 68Ge/68Ga images of
68Ge/68Ga to simplify bias calculation unless PET scanner manufac-
turers are willing to provide the necessary software.
After necessary corrections to PET image data, the resulting derived
values are listed in Tables 2 and 3. We decided a priori to censor site
identities for individual results to facilitate participation of community
PET imaging centers located in the states of Alaska and Washington.
As a consequence, the site numbers in Tables 2 and 3 do not cor-
respond to the order of sites in Table 1. These results showed the fol-
lowing two notable effects: There was variability between sites in both
absolute measurement (kBq/ml) and SUV, and this variability changed
in time. Closer inspection shows that dose calibrator measurement
biases do not always match PET scanner measurement biases and
combined dose calibrator and PET scanner measurement biases do
not cancel out to reduce SUV biases, as is sometimes proposed [8–10].
The reasons for exceptionally large bias in dose calibrator and PET
scanner measurement errors for the second scan at site 1 in Table 2
Table 2. Longitudinal Errors in PET Dose Calibrator and Scanner Measurements (Unitless).
Site* DC† Error Scan 1 DC† Error Scan 2 Change in DC† Error PET‡ Error Scan 1 PET‡ Error Scan 2 Change in PET‡ Error
1 9.0% −50.3%§ −59.3% −3.4% −26.8% −23.4%
2 8.4% 8.7% 0.3% 13.2% 1.1% −12.0%
3 8.1% 8.8% 0.7% 6.0% 6.4% 0.4%
4 −0.4% −2.5% −2.1% −7.6% −14.2% −6.6%
5 −0.3% −3.8%§ −3.5% −6.6% −15.1% −8.5%
6 1.8% 2.1% 0.3% −18.2% −7.1% 11.1%
*Site numbers are same in Tables 2 and 3 but in different order than in Table 1.
†Dose calibrator activity measurement.
‡PET scanner activity concentration measurement.
§Dose calibrator settings different for second measure.
Table 3. Biases in PET SUV Measurements (Unitless).
Site* SUV Error† Scan 1 SUV Error† Scan 2 Change in SUV Error‡
1 −11.3% 47.3% 58.6%
2 4.4% −6.9% −11.4%
3 −1.9% −2.2% −0.3%
4 −7.2% −12.0% −4.7%
5 −6.3% −11.7% −5.4%
6 −19.7% −9.0% 10.7%
*Site numbers are same in Tables 2 and 3 but in different order than in Table 1.
†SUV biases calculated by Equation 8.
‡Change in SUV error does not equal column 3 with column 2 in all cases due to rounding errors.
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are not conclusively known. The second scan measurements at this
site were conducted and reported by local staff, and the site declined
our offers for subsequent investigation of the large measurement
biases. The corresponding range of change in SUV bias in Table 3
from −11% to 59% was larger than expected on the basis of the
reported coefficients of variation from repeat measures of 68Ge/
68Ga phantoms that range from a low 0.2% (15-cm mean ROIs for
80-minute scans on same day, n = 20) [13] to 3.7% (15-cm mean
ROIs for images captured months apart on same scanner, n = 13)
[14] to 43% (1.2-cm mean ROIs on small source with 2.5-cm diam-
eter captured months apart at nine different national imaging centers
using local analyses) [19]. We speculate that the higher than expected
measurement biases may be due to the 9 to 15 operator-dependent
steps involved in the calibration process [10]. Another potential source
of error is longitudinal drift in PET scanner sensitivity relative to the
typically more stable dose calibrator sensitivity. At this same site, the
dose calibrator measurement bias changed from +9% in scan 1 to
−50% in scan 2. This change in error is suspected to be due to an
incorrect change in the calibration setting for the dose calibrator
that was applied sometime between scans 1 and 2, though their self-
reported new calibration setting was consistent with the current recom-
mendations of their dose calibrator’s manufacturer.
This study only evaluated six sites at two time points for a total of
12 PET scanner and 12 dose calibrator measurements (not including
the eight 68Ge/68Ga repeat scans of the scanner surrogate source).
Thus, the measured biases should not be considered an estimate of
the ensemble of all PET imaging sites. Because the potential error
is unbounded, there may not be meaningful statistics from such an
analysis. We are now conducting a multiyear study of a larger number
of sites where the cross-calibration process is used before repeat FDG
scans of patients to enable assessment of measurement error associ-
ated with instrumentation separately from error associated with imag-
ing patients. Although a small number of sites were evaluated, we
believe that this is sufficient to demonstrate the potential for error at
all sites. Another limitation is that 68Ga decay generates a small num-
ber (∼3%) of prompt γ rays [20]. These prompt γ rays can lead to
triple coincidences, which may be handled differently by each scanner
thus leading to small variations between scanners for equivalent PET
scanner surrogate sources.
The use of a dose calibrator and PET scanner cross-calibration pro-
cess as described here has several considerations. The potential value
was demonstrated by measurement of varying bias across sites and time.
The procedures used in this study were complicated by the use of an
18F scan protocol with a 68Ge/68Ga source in the PET scanner. This
would be considerably simplified by the adoption of a routine 68Ge/
68Ga scan protocol. This points out that there are two different modes
of use for the cross-calibration process: 1) checking the scanner and
dose calibrator measurements for consistency, as was done in this
study, or 2) integration of the cross-calibration sources directly
into the scanner calibration process. The latter approach depends on
the specific PET scanner calibration process, which varies between
scanner manufacturers.
Conclusions
The results indicate that bias in serial SUV measurements on the same
scanner varies over time and between scanner sites. The conventional
wisdom of SUVs having less error than other PET measurements due
to any biases in PET scanner and dose calibrator measurements can-
celing each other out during SUV calculation is not supported by the
large range of changes in SUV error from −11% to 59% in Table 3.
The findings suggest that use of PET dose calibrator and scanner
cross-calibration kits will be useful in multicenter imaging trials to
both assess bias and enable correction of biases due to instrumentation
factors in serial PET studies. Methods could be adopted to improve
data quality either by prospective scanner calibration or retrospective
post hoc corrections.
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